| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $197,759 | 39 | 100 |
Sells | $0 | 0 | 0 |
| MOORE WILLIAM M | director | 9 | $113,016 | 0 | $0 | $113,016 |
| HUSS BEVERLY A | director | 1 | $31,500 | 0 | $0 | $31,500 |
| Shuda Scott | director | 1 | $25,748 | 0 | $0 | $25,748 |
| Dizon Romeo R | Chief Financial Officer | 25 | $17,497 | 0 | $0 | $17,497 |
| Mercer Patrick | President and CEO | 3 | $9,998 | 0 | $0 | $9,998 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Over the last 12 months, insiders at IRIDEX Corporation have bought $197,759 and sold $0 worth of IRIDEX Corporation stock.
On average, over the past 5 years, insiders at IRIDEX Corporation have bought $115,044 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOORE WILLIAM M (director) — $113,016. HUSS BEVERLY A (director) — $31,500. Shuda Scott (director) — $25,748.
The last purchase of 250 shares for transaction amount of $240 was made by Mercer Patrick (President and CEO) on 2025‑06‑13.
| 2025-06-13 | Mercer Patrick | President and CEO | 250 0.0015% | $0.96 | $240 | +3.17% | ||
| 2025-06-13 | MOORE WILLIAM M | director | 20,000 0.1227% | $0.97 | $19,372 | +3.17% | ||
| 2025-06-12 | MOORE WILLIAM M | director | 20,000 0.1235% | $0.97 | $19,494 | +1.00% | ||
| 2025-06-11 | MOORE WILLIAM M | director | 10,000 0.0617% | $0.96 | $9,627 | +1.97% | ||
| 2025-06-11 | Dizon Romeo R | Chief Financial Officer | 245 0.0015% | $0.96 | $236 | +1.97% | ||
| 2025-06-10 | Dizon Romeo R | Chief Financial Officer | 335 0.0021% | $0.98 | $327 | -0.62% | ||
| 2025-06-09 | Dizon Romeo R | Chief Financial Officer | 500 0.003% | $0.99 | $495 | -1.66% | ||
| 2025-06-06 | Dizon Romeo R | Chief Financial Officer | 1,500 0.0089% | $0.97 | $1,455 | +0.21% | ||
| 2025-06-03 | Dizon Romeo R | Chief Financial Officer | 100 0.0006% | $0.99 | $99 | -1.24% | ||
| 2025-06-02 | Dizon Romeo R | Chief Financial Officer | 100 0.0006% | $1.00 | $100 | -2.79% | ||
| 2025-05-29 | Dizon Romeo R | Chief Financial Officer | 200 0.0011% | $0.98 | $197 | +0.05% | ||
| 2025-05-28 | Dizon Romeo R | Chief Financial Officer | 200 0.0012% | $0.95 | $190 | +3.88% | ||
| 2025-05-27 | Dizon Romeo R | Chief Financial Officer | 100 0.0006% | $1.00 | $100 | -2.47% | ||
| 2025-05-23 | Dizon Romeo R | Chief Financial Officer | 100 0.0006% | $1.00 | $100 | -2.35% | ||
| 2025-05-22 | Dizon Romeo R | Chief Financial Officer | 200 0.0012% | $1.00 | $201 | -3.14% | ||
| 2025-05-15 | MOORE WILLIAM M | director | 2,500 0.0149% | $1.00 | $2,503 | -1.88% | ||
| 2025-05-14 | MOORE WILLIAM M | director | 15,000 0.0983% | $1.10 | $16,506 | -10.74% | ||
| 2025-05-14 | Dizon Romeo R | Chief Financial Officer | 460 0.003% | $1.10 | $506 | -10.74% | ||
| 2025-05-13 | Dizon Romeo R | Chief Financial Officer | 1,305 0.0079% | $1.11 | $1,451 | -11.12% | ||
| 2025-05-12 | Dizon Romeo R | Chief Financial Officer | 100 0.0006% | $1.16 | $116 | -14.79% |
| Mercer Patrick | President and CEO | 386730 2.3035% | $377,564.50 | 3 | 0 | |
| MOORE WILLIAM M | director | 188650 1.1237% | $184,179.00 | 57 | 0 | +10.85% |
| Shuda Scott | director | 129523 0.7715% | $126,453.30 | 3 | 0 | +1.49% |
| HUSS BEVERLY A | director | 92639 0.5518% | $90,443.46 | 1 | 0 | |
| Dizon Romeo R | Chief Financial Officer | 15245 0.0908% | $14,883.69 | 25 | 8 | |
| BlueLine Catalyst Fund IX, L.P. | 2559122 15.2428% | $2.5M | 18 | 0 | +10.82% | |
| BlueLine Capital Partners II, L.P. | 10 percent owner | 2508100 14.9389% | $2.45M | 2 | 0 | +27.27% |
| BlueLine Partners, L.L.C. | 10 percent owner | 2465222 14.6836% | $2.41M | 9 | 0 | |
| Acuta Capital Fund, LP | 10 percent owner | 1344720 8.0095% | $1.31M | 33 | 0 | <0.0001% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 1320000 7.8623% | $1.29M | 17 | 0 | +39.25% | |
| BOUTACOFF THEODORE A | President, CEO and Chairman | 159047 0.9473% | $155,277.59 | 1 | 19 | |
| Grove Robert Earle | director | 93364 0.5561% | $91,151.27 | 8 | 0 | +0.21% |
| DONOVAN JAMES L | VP Corp Business Development | 82510 0.4915% | $80,554.51 | 0 | 1 | |
| Steckel Ronald | VP, Operations | 65625 0.3909% | $64,069.69 | 0 | 30 | |
| NAUMANN-ETIENNE RUEDIGER | director | 64433 0.3838% | $62,905.94 | 4 | 11 | +37.2% |
| Mackaness James H | CFO and COO | 45052 0.2683% | $43,984.27 | 1 | 31 | |
| GARRETTSON GARRETT A | director | 39441 0.2349% | $38,506.25 | 5 | 2 | +27.28% |
| HAWKINS JAMES B | director | 31294 0.1864% | $30,552.33 | 0 | 4 | |
| HAMMOND DONALD L | director | 23750 0.1415% | $23,187.13 | 0 | 4 | |
| Devi Nandini | 10420 0.0621% | $10,173.05 | 3 | 0 | <0.0001% | |
| Caldwell Barry G | President and CEO | 6000 0.0357% | $5,857.80 | 1 | 0 | <0.0001% |
| Marcellino George R | director | 1289 0.0077% | $1,258.45 | 0 | 1 | |
| FITCH SANFORD | director | 0 0% | $0 | 4 | 1 | +5.46% |
| ARIAS EDUARDO | Sr. VP, Global Sales | 0 0% | $0 | 0 | 17 | |
| POWERS TIMOTHY S | VP, Operations | 0 0% | $0 | 0 | 2 | |
| Todd Donald J | Sr. VP of Marketing | 0 0% | $0 | 0 | 1 |
| Increased Positions | 9 | +27.27% | 96,658 | +2.99% |
| Decreased Positions | 13 | -39.39% | 178,606 | -5.53% |
| New Positions | 2 | New | 32,255 | New |
| Sold Out Positions | 5 | Sold Out | 152,771 | Sold Out |
| Total Postitions | 29 | -12.12% | 3M | -2.54% |
| Paragon Associates & Paragon Associates Ii Joint Venture | $1,190.00 | 5.88% | 1M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $668.00 | 3.3% | 561,096 | 0 | 0% | 2024-12-31 |
| Amh Equity Ltd | $596.00 | 2.95% | 501,121 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $454.00 | 2.24% | 381,160 | -16,200 | -4.08% | 2024-12-31 |
| Geode Capital Management, Llc | $156.00 | 0.77% | 131,172 | 0 | 0% | 2024-12-31 |
| Ars Investment Partners, Llc | $131.00 | 0.65% | 110,060 | -3,505 | -3.09% | 2024-12-31 |
| Bridgeway Capital Management, Llc | $83.00 | 0.41% | 70,000 | -6,975 | -9.06% | 2024-12-31 |
| Citadel Advisors Llc | $81.00 | 0.4% | 67,653 | +17,377 | +34.56% | 2024-12-31 |
| Apexium Financial, Lp | $78.00 | 0.39% | 65,695 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $67.00 | 0.33% | 56,668 | -696 | -1.21% | 2025-03-31 |